Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher P Evans

Showing results (131-140 of 208) with videos related to

Pageof 21
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|December 7, 2007
An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cellsXu-Bao Shi, Lingru Xue, Joy Yang, et al.
Cancer|March 29, 2016
A phase 2 clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancerHelen Chow, Paramita M Ghosh, Ralph deVere White, et al.
Molecular Cancer Therapeutics|May 14, 2017
Niclosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate CancerChengfei Liu, Cameron M Armstrong, Wei Lou, et al.
Cancer|March 18, 2011
Secondary malignancies among nonseminomatous germ cell tumor cancer survivorsKarim Chamie, Eric A Kurzrock, Christopher P Evans, et al.
Nature|August 16, 2013
lncRNA-dependent mechanisms of androgen-receptor-regulated gene activation programsLiuqing Yang, Chunru Lin, Chunyu Jin, et al.
Clinical Genitourinary Cancer|February 15, 2008
The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trialKaren G Chee, Jeff Longmate, David I Quinn, et al.
Molecular Cancer Therapeutics|July 17, 2019
AKR1C3 Promotes AR-V7 Protein Stabilization and Confers Resistance to AR-Targeted Therapies in Advanced Prostate CancerChengfei Liu, Joy C Yang, Cameron M Armstrong, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 26, 2009
The Src inhibitor AZD0530 blocks invasion and may act as a radiosensitizer in lung cancer cellsPhillip R Purnell, Philip C Mack, Clifford G Tepper, et al.
Cancer|November 24, 2004
Society of Urologic Oncology position statement: redefining the management of hormone-refractory prostate carcinomaSam S Chang, Mitchell C Benson, Steven C Campbell, et al.
Pharmacological Research|February 11, 2023
Allosteric inhibition of HSP70 in collaboration with STUB1 augments enzalutamide efficacy in antiandrogen resistant prostate tumor and patient-derived modelsPengfei Xu, Joy C Yang, Shu Ning, et al.
Pageof 21

Showing results (131-140 of 208) with videos related to

Sort By:
Pageof 21
Proceedings of the National Academy of Sciences of the United States of America|December 7, 2007
An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cellsXu-Bao Shi, Lingru Xue, Joy Yang, et al.
Cancer|March 29, 2016
A phase 2 clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancerHelen Chow, Paramita M Ghosh, Ralph deVere White, et al.
Molecular Cancer Therapeutics|May 14, 2017
Niclosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate CancerChengfei Liu, Cameron M Armstrong, Wei Lou, et al.
Cancer|March 18, 2011
Secondary malignancies among nonseminomatous germ cell tumor cancer survivorsKarim Chamie, Eric A Kurzrock, Christopher P Evans, et al.
Nature|August 16, 2013
lncRNA-dependent mechanisms of androgen-receptor-regulated gene activation programsLiuqing Yang, Chunru Lin, Chunyu Jin, et al.
Clinical Genitourinary Cancer|February 15, 2008
The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trialKaren G Chee, Jeff Longmate, David I Quinn, et al.
Molecular Cancer Therapeutics|July 17, 2019
AKR1C3 Promotes AR-V7 Protein Stabilization and Confers Resistance to AR-Targeted Therapies in Advanced Prostate CancerChengfei Liu, Joy C Yang, Cameron M Armstrong, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 26, 2009
The Src inhibitor AZD0530 blocks invasion and may act as a radiosensitizer in lung cancer cellsPhillip R Purnell, Philip C Mack, Clifford G Tepper, et al.
Cancer|November 24, 2004
Society of Urologic Oncology position statement: redefining the management of hormone-refractory prostate carcinomaSam S Chang, Mitchell C Benson, Steven C Campbell, et al.
Pharmacological Research|February 11, 2023
Allosteric inhibition of HSP70 in collaboration with STUB1 augments enzalutamide efficacy in antiandrogen resistant prostate tumor and patient-derived modelsPengfei Xu, Joy C Yang, Shu Ning, et al.
Pageof 21